Primobolan vs Masteron: Mechanism of Action and Side Effects Compared
Primobolan (methenolone) and Masteron (drostanolone) are two anabolic-androgenic steroids often discussed together because both are marketed as "mild" or "cosmetic" compounds. Both are controlled substances in the US, prohibited in sport, and carry real health risks. Our editorial team compares their chemistry, mechanisms and documented side effects, without providing any usage guidance.
What these two compounds are
Methenolone, sold historically under the brand Primobolan, is a derivative of dihydrotestosterone (DHT). It has existed in both an oral (methenolone acetate) and an injectable (methenolone enanthate) form. It was originally developed for medical use, including some wasting conditions.
Drostanolone, known as Masteron, is also a DHT derivative. It was once used medically as an adjunct treatment for certain breast cancers because of its anti-estrogenic properties, a use long since replaced by better drugs.
Both are synthetic anabolic-androgenic steroids (AAS): molecules engineered from the testosterone/DHT skeleton to alter the balance of anabolic (tissue-building) and androgenic (masculinizing) effects, and to change how the body metabolizes them.
Neither is a current mainstream prescription medicine in the US. Products circulating outside medical channels are unregulated, and their identity and purity cannot be assumed from the label.
Chemistry and mechanism of action
Like all AAS, methenolone and drostanolone work primarily by binding the androgen receptor in muscle and other tissues, promoting protein synthesis and influencing gene expression. Both are derived from DHT, so neither converts to estrogen through the aromatase enzyme.
Drostanolone has a notable additional property: it can weakly inhibit aromatase and interact with the estrogen pathway, which is the basis of its former use in breast cancer. This is often described in fitness circles as an "anti-estrogen" effect, though it is weak compared with dedicated medicines.
| Property | Methenolone (Primobolan) | Drostanolone (Masteron) |
|---|---|---|
| Parent molecule | DHT derivative | DHT derivative |
| Aromatizes to estrogen | No | No |
| Estrogen-pathway effect | Minimal | Weak anti-estrogen activity |
| Historic medical use | Wasting conditions, anemia | Breast cancer adjunct |
| Androgenic character | Relatively moderate | Relatively androgenic |
Because both are DHT-based and non-aromatizing, marketing claims that they cause less water retention than testosterone. However, non-aromatizing androgens carry their own problems, particularly effects on cholesterol and hair, which are frequently downplayed.
Being 5-alpha reduced derivatives, these compounds act strongly on androgen-sensitive tissues such as the scalp and prostate, which shapes their side-effect profile.
Documented and expected side effects
All AAS suppress the body's own production of testosterone through negative feedback on the brain and pituitary, reducing luteinizing and follicle-stimulating hormones. This can shrink the testes and impair fertility, sometimes for a prolonged period after stopping.
- Suppression of natural testosterone and possible infertility
- Unfavorable cholesterol changes, especially lower HDL, common with non-aromatizing DHT derivatives
- Androgenic effects: acne, oily skin, and male-pattern hair loss in predisposed people
- In women, virilization, including voice deepening and facial hair, some of it irreversible
- Possible increases in blood pressure and cardiovascular strain
Non-aromatizing androgens like these tend to be hard on the lipid profile, lowering protective HDL cholesterol. Over time, adverse lipid changes contribute to cardiovascular risk, a concern documented across AAS use in the Endocrine Society's scientific statement.
Because drostanolone is relatively androgenic, hair loss and acne are commonly reported. Methenolone is often called gentler, but "gentler" is relative to other steroids, not to not using them at all.
Product quality adds risk: counterfeit or mislabeled vials are common in the underground market, and non-sterile injectables can cause abscesses and bloodborne infections.
Legal status and doping rules
In the United States, both methenolone and drostanolone are Schedule III controlled substances under the Anabolic Steroid Control Act. Possessing or distributing them without a valid prescription is a criminal offense.
In the UK, anabolic steroids are Class C controlled drugs; personal possession has different treatment from supply, but importation and supply are offenses. The European picture varies by country but generally restricts these compounds.
In sport, both are prohibited at all times under section S1 (anabolic agents) of the World Anti-Doping Agency list. Methenolone and drostanolone are among the substances most frequently detected in anti-doping testing, and detection windows for the injectable esters can be long.
An athlete testing positive faces bans and reputational damage. There is no "safe" way to use these compounds within tested competition.
Why "mild" is misleading
The reputation of both drugs as "cosmetic" or "mild" rests mostly on the absence of estrogenic bloating, not on genuine safety. Suppression of the hormonal axis, adverse cholesterol changes and androgenic effects apply to both.
Framing one steroid as safer than another encourages a false sense of security. The honest comparison is between two controlled drugs that share most of the same hazards.
For anyone pursuing physique or performance goals, legal and evidence-based methods, structured training, nutrition and adequate recovery, avoid the legal, hormonal and cardiovascular risks entirely.
Editorial conclusions
Methenolone and drostanolone are both DHT-derived anabolic steroids that do not aromatize; drostanolone additionally has weak anti-estrogen activity and is more androgenic.
They share the central AAS risks: hormonal suppression, worsened cholesterol, androgenic side effects and, in women, irreversible virilization. Both are controlled substances and banned in sport.
The "mild" label refers mainly to the lack of estrogenic bloating and should not be read as a sign of safety.
Related editorial reading: how AAS suppress natural testosterone, the cardiovascular effects of non-aromatizing steroids, and how anti-doping tests detect anabolic agents.
References
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
- Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse. Drug Alcohol Depend. 2008;98(1-2):1–12.
- Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010;95(4):1533–1543.
- World Anti-Doping Agency. The Prohibited List. Montreal: WADA; 2024.
- Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
- https://farmaciadeportivaes.com/
